Jae Park Explains CAR T-cell Therapy
Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
Jae Park, MD, Memorial Sloan Kettering Cancer Center, explains CAR T-cell therapy, which is currently being investigated in patients with acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma.
CAR T-cells are artificial T-cell receptors that are made by combining a domain from an antibody to the domain of a T-cell. This makes the therapy effective because it can signal and act like a T-cell and bind like an antibody, taking advantage of both bodies, Park explains. Also incorporating the T-cell allows the therapy to be a “living drug” that can grow and replicate, not limited by its determined half-life.
